文献速递免疫规划妇幼与学校卫生

澳大利亚高风险儿童肺炎球菌疫苗覆盖率:基于记录链接的估算

Estimating pneumococcal vaccine coverage among Australian Indigenous children and children with medically at-risk conditions using record linkage.
PubMed 文献 · Vaccine · 2021-02-20

该研究利用澳大利亚两个州的免疫接种与住院记录链接数据,评估2001年7月至2012年12月出生儿童中按风险分组的肺炎球菌疫苗覆盖率。结果显示,2005年引入普遍PCV接种后,基础免疫覆盖率大幅提升,但高危儿童的额外推荐加强剂量覆盖率极低。

要点

  • 2005-2012年出生儿童PCV第3剂覆盖率在1岁时原住民为83%、医学高危为91%、其他儿童为92%。
  • 医学高危儿童PCV第4剂覆盖率由2001-2004年的1%升至2005-2012年的9%。
  • 高危儿童6岁时PPV23覆盖率在两个出生队列中均仅为3%。

核心结论

  • 医学高危儿童额外推荐加强剂量覆盖率极低,原住民儿童也仅中等。
  • 若在高风险人群中推荐额外PCV剂量,需采取措施改善实施。

研究设计与样本

  • 利用澳大利亚两州链接的免疫接种和住院数据,纳入2001年7月至2012年12月出生儿童。
  • 通过住院诊断代码确定医学风险状况,采用既定算法判定原住民身份。
  • 比较2001-2004年与2005-2012年出生队列的疫苗覆盖率。

主要发现

  • 2001-2004年出生队列1岁时PCV第3剂覆盖率:原住民37%、医学高危15%、其他儿童11%。
  • 2005-2012年出生队列相应覆盖率分别升至83%、91%和92%。
  • 医学高危儿童2岁时PCV第4剂覆盖率:2001-2004年出生为1%,2005-2012年出生为9%;6岁时PPV23覆盖率两个队列均为3%。
  • 符合条件原住民儿童3岁时PPV23覆盖率:2001-2004年出生为45%,2005-2012年出生为51%。

临床怎么用

  • 应关注医学高危儿童额外PCV加强剂量的接种实施,覆盖率远低于基础免疫。
  • 原住民儿童PPV23覆盖率虽有提升但仍有限,需加强接种提醒与补种。

局限性

  • 仅基于两个州的链接数据,外推需谨慎。
  • 医学风险状况依赖住院诊断代码,可能低估或漏判。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Risk-based recommendations are common for pneumococcal vaccines but little is known about their uptake. In Australia, pneumococcal conjugate vaccine (PCV) was funded only for Aboriginal or Torres Strait Islander (Indigenous) children and those with underlying medical conditions in 2001, and then there were different booster dose recommendations depending on risk after the introduction of universal PCV vaccination in 2005. METHODS: We measured coverage of PCV dose 3 and additional PCV and 23-valent pneumococcal polysaccharide vaccine (PPV23) doses by risk group among children born in July 2001-December 2012 in two Australian states using linked immunisation and hospitalisation data (available until December 2013). We ascertained medical risk conditions using hospitalisation diagnosis codes and Indigenous status using an established algorithm, comparing coverage for children born pre (2001-2004) and post (2005-2012) universal PCV funding. RESULTS: Among 1.3 million children, 63,897 (4.9%) were Indigenous and 32,934 (2.5%) had at least one medically at-risk condition identified by age 6 months. For births in 2001-2004, coverage for PCV dose 3 by 1 year of age was 37% for Indigenous, 15% for medically at-risk and 11% in other children, increasing to 83%, 91% and 92%, respectively for births in 2005-2012. In children with medically at-risk conditions, PCV dose 4 coverage by 2 years was 1% for 2001-2004 births, increasing to 9% for 2005-2012 births, with PPV23 coverage by 6 years 3% in both cohorts. Among eligible Indigenous children, PPV23 coverage by 3 years was 45% for 2001-2004 births and 51% for 2005-2012 births. CONCLUSIONS: Coverage with additional recommended booster doses was very low among children with medical conditions, and only modest among Indigenous children. If additional PCV doses are recommended for some risk groups, especially in the context of routine schedules with reduced doses (e.g. 2 + 1 and 1 + 1), measures to improve implementation will be required.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Kabir A, Newall AT, Randall D, et al. Estimating pneumococcal vaccine coverage among Australian Indigenous children and children with medically at-risk conditions using record linkage. Vaccine. 2021. PMID: 33622589. doi:10.1016/j.vaccine.2021.02.015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。